Answer: Monitoring postmarketing study commitments. The FDA lacks an effective system for monitoring postmarketing study commitments. See the latest OIG Report, dated June 2006.
{ 0 comments }
Medicare Fraud News, Breaking Headlines and Insight from the Qui Tam Perspective
Posts tagged as:
Answer: Monitoring postmarketing study commitments. The FDA lacks an effective system for monitoring postmarketing study commitments. See the latest OIG Report, dated June 2006.
{ 0 comments }
A pharmaceutical company can violate the false claims act by submitting false statements in connection with drug applications and other records to the United States Food and Drug Administration (”FDA”). For example, clinical trial results can involve false statements; and subsequent false statements and claims in marketing materials promoted to the medical community and other [...]
{ 0 comments }